Reviewed July 2005
Radionuclide therapy in the form of systemic Strontium-89 therapy may be useful in the palliation of hormone resistant metastatic carcinoma when multiple skeletal sites are involved in various carefully selected patients. Refer such patients to Radiation Oncology for consideration.
